MabThera/Rituxan

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

from blockbusters Avastin, Herceptin and Mabthera/Rituxan.

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera.

MSD launches EU’s first biosimilar Herceptin in UK

Roche has particularly high exposure to biosimilar erosion in the coming years in its first-generation antibody products - with Avastin (bevacizumab) and MabThera (rituximab) also under threat along with Herceptin - but

The good, the bad and the ugly

The main drivers of revenue for Roche are well-established, standard-of-care blockbuster oncology drugs including Rituxan, Herceptin and Avastin. ... Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and

NICE backs Roche’s Gazyvaro after initial rejection

clinical profile justified premium pricing over Mabthera (rituximab), Roche’s older drug for the FL indication. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]